Spritz-OM

Video credit: Guru Productions and Channel 9

Spritz-OM is a novel patent-protected nasal therapy set to prevent ear infections.  Almost every child experiences a middle ear infection by their 2nd birthday. One in 4 suffer repeat infections, often resulting in hearing loss and requiring antibiotics and surgery. Spritz-OM targets the major pathogen that is responsible for over 50% of the 700 million annual ear infections worldwide. That pathogen is nontypeable Haemophilus influenzae (NTHi), which is also a major pathogen in sinusitis, pneumonia and chronic lung diseases. There are no approved preventative therapies that successfully target this pathogen.

Preventing over half of the world’s ear infections with a therapy such as Spritz-OM will significantly improve health and educational outcomes on a global scale. Less ear infections means fewer GP visits and antibiotic scripts, less time off work/school for families, shortened hospital waiting lists, reduced demand for audiology and speech therapy, and improved educational outcomes; all permitting redirection of healthcare and education resources, in addition to providing a solution to reduce antibiotic consumption to curb the alarming rise in antimicrobial resistance.

Read more in our recent publication on this in the Journal of Infectious Diseases.